ARC
AEGR

Absolute Return Capital’s Aegerion Pharmaceuticals AEGR Stock Holding History

Absolute Return Capital’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-8,871
Closed -$285K – 1145
2014
Q2 		$285K Sell
8,871
-2,959
-25% -$110K ﹤0.01% 957
2014
Q1 		$546K Buy
+11,830
New +$694K 0.01% 825

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Absolute Return Capital's AEGR Position: Q3 2014 in Review

Absolute Return Capital sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2014, closing a stake of 8,871 shares — an estimated $285K sold.

Absolute Return Capital first reported a position in AEGR in Q1 2014 and held it in 2 quarters. The position peaked at $546K in Q1 2014. 131 funds tracked by Wall St. Rank hold AEGR as of Q3 2014.

  • Absolute Return Capital reported no remaining Aegerion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Absolute Return Capital sold 8,871 Aegerion Pharmaceuticals shares in Q3 2014, an estimated $285K.
  • Absolute Return Capital first reported a position in Aegerion Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Absolute Return Capital's Aegerion Pharmaceuticals position peaked at $546K in Q1 2014.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.